ArticleBMC infectious diseases2025
Molecular and biological characteristics of two rare bloodstream Candida isolates: Candida nonsorbophila and Candida sonorensis.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe incidence of new infections caused by rare Candida species has been steadily increasing, particularly in immunocompromised patients. This study investigates two rare Candida species responsible for Candida bloodstream infections and explores their molecular characteristics.
methodsClinical Candida strains were continuously isolated from the lower respiratory tract and blood specimens of a patient. Identification was performed using conventional culture techniques, ITS sequencing, and whole-genome sequencing. Additionally, antifungal susceptibility testing, phylogenetic analysis, macrophage survival assays, and in vivo survival experiments were conducted to evaluate the antifungal resistance, infection source, and pathogenicity of the isolates.
resultsMolecular identification confirmed that the RP (pinkish-purple colonies from respiratory specimens), RW (pinkish-white colonies from respiratory specimens), and BP (pinkish-purple colonies from peripheral blood) strains were Candida nonsorbophila, while the BW (pinkish-white colonies from peripheral blood) strain was identified as Candida sonorensis. Phylogenetic analysis revealed that the RP strain from the lower respiratory tract and the BP strain from the bloodstream belonged to the same clonal lineage, suggesting that the pulmonary isolate entered the bloodstream, resulting in candidemia. Antifungal susceptibility testing showed that C. nonsorbophila RW strain exhibited significant resistance to fluconazole, likely due to the E70D mutation in the ERG11 gene. Both C. sonorensis and C. nonsorbophila exhibited relatively weak virulence, with no significant differences in pathogenicity between single-strain infections and mixed infections of both species (P > 0.05).
conclusionThis study successfully isolated C. nonsorbophila and C. sonorensis from clinical specimens, providing detailed microbiological and molecular characterization. Rare fungal infections in immunocompromised patients require careful consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.